volasertib
Permission to pause: making treatment breaks part of the cancer care conversation
Exploring how empathetic, patient-centred communication can make planned treatment breaks easier to discuss as part of cancer care.
Roche and Oxford BioTherapeutics enter oncology partnership worth over $1bn
The companies will aim to discover new antibody-based therapeutics for cancer
FDA approves Shorla Oncology’s Imkeldi to treat leukaemia and other cancers
The solution is an advanced liquid formulation of the tyrosine kinase inhibitor imatinib mesylate
Innovative Trials Announces New Charity Partnerships
Innovative Trials, a global patient recruitment and retention company, has just announced GOSH Charity and Oliver Patch Project as their charity partners of the year
Eli Lilly and Radionetics Oncology enter $140m radiopharma partnership
The strategic agreement also gives Lilly the exclusive right to acquire the biotech for $1bn
Envision Analogue – An Introduction
Powered by primary payer market research, Envision is an online platform that provides forward-looking evaluations and comprehensive strategic direction for market access viability after an oncology product has received positive...
Ipsen enters $900m licensing agreement for Sutro Biopharma’s ADC candidate
STRO-003 will be the first ADC candidate to be added to Ipsen’s portfolio
New technique enables study of immune response to cancer using archived tissue samples
FUME-TCRseq was shown to successfully read formalin-fixed paraffin-embedded tissue samples
Gilead and Merus announce oncology partnership worth over $1.5bn
The companies will aim to discover dual tumour-associated antigens targeting trispecific antibodies
Researchers develop screening tool to investigate mechanisms behind multiple diseases
The technique will assess genetic changes in cells behind cancer, autoimmunity and neurodegeneration
‘Click chemistry’ system used to map new class of drug targets in cancer and immunology
The novel tagging system won the Nobel Prize in Chemistry in October 2022
Gilead gains rights to Compugen’s immunotherapy programme in deal worth $848m
The high affinity antibody blocks the interaction between IL-18 binding protein and IL-18